# TGFB2

Source: https://onco.cc/targets/tgfb2/  
OnCo record `tgfb2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TGFB2 (Transforming growth factor beta-2 proprotein) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.

## Summary

Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively. Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2.

Open Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes clinical 0.65, literature 0.99, genetic association 0.59, somatic mutation 0.19, animal model 0.51).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: transforming growth factor beta 2; Transforming growth factor beta-2 proprotein
- Tags: cancer-genes-wave
- Symbol: TGFB2
- Class: other
- Biology: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively. Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2. Multifunctional protein that regulates various processes such as angiogenesis and heart development. Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains remain non-covalently linked rendering TGF-beta-2 inactive during storage in extracellular matrix. At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 and maintain it in a latent state during storage in extracellular milieus. Location: Secreted, extracellular space, extracellular matrix; Secreted (UniProt). Locus 1q41 (HGNC).
- Where found: Myelodysplastic syndromes / neoplasms: Open Targets association 0.57 with myelodysplastic syndrome (MONDO_0018881)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.92; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:11768: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11768
- UniProt P61812: https://www.uniprot.org/uniprotkb/P61812/entry
- NCBI Gene 7042: https://www.ncbi.nlm.nih.gov/gene/7042
- Ensembl ENSG00000092969: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000092969

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)

---
JSON: https://onco.cc/api/v1/entities/tgfb2.json